The Joint Corp Q2 revenue beats estimates, reiterates 2026 outlook
JYNT•Drivers and key details
The company said revenue growth reflected the transition to a pure-play franchisor model and clinic portfolio optimization.
It said increased adoption of flexible plan options drove stronger patient retention, while refranchising and a streamlined structure improved operating efficiency and free cash flow.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $15.2 million | $14.57 million (4 analysts) |
| Q2 EPS | $0.05 |
The current average analyst rating on the shares is "hold," with 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for The Joint Corp is $9.00, about 8% above its August 5 closing price of $8.33.
The stock recently traded at 29 times the next 12-month earnings, versus a P/E of 37 three months ago.
Q2 revenue beats estimates
The Joint Corp's second-quarter revenue rose 14% and beat analyst expectations, while adjusted EBITDA from continuing operations increased sharply year-over-year.
The company said it repurchased $677,000 in shares and completed three regional developer territory buybacks.
